Keyword Analysis & Research: dostarlimab
Keyword Research: People who searched dostarlimab also searched
Search Results related to dostarlimab on Search Engine
-
Dostarlimab - Wikipedia
https://en.wikipedia.org:443/wiki/Dostarlimab
WEBDostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
DA: 15 PA: 83 MOZ Rank: 18
-
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
https://www.nejm.org:443/doi/full/10.1056/NEJMoa2216334
WEBMar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of...
DA: 34 PA: 62 MOZ Rank: 92
-
Dostarlimab Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com:443/mtm/dostarlimab.html
WEBJun 21, 2022 · Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery. Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.
DA: 40 PA: 69 MOZ Rank: 1
-
FDA grants accelerated approval to dostarlimab-gxly for dMMR …
https://www.fda.gov:443/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
WEBJul 18, 2023 · On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR)...
DA: 67 PA: 7 MOZ Rank: 49
-
Dostarlimab: A Review - PubMed
https://pubmed.ncbi.nlm.nih.gov:443/35892341/
WEBJul 26, 2022 · Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies. Keywords: anti-PD-1 antibody; clinical trials; dostarlimab; immunotherapy.
DA: 65 PA: 20 MOZ Rank: 44
-
Dostarlimab: A Review - PMC - National Center for Biotechnology …
https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9331682/
WEBJul 26, 2022 · Dostarlimab (also referred to as TSR-042 or Jemperli, commercial name) is a humanized mAb of the IgG4 isotype, produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells that binds PD-1 on T cells and blocks interactions with its ligands PD-L1 and PD-L2, activating immune responses.
DA: 72 PA: 79 MOZ Rank: 35
-
Dostarlimab as a Miracle Drug: Rising Hope against Cancer …
https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9406030/
WEBAug 8, 2022 · In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the …
DA: 65 PA: 46 MOZ Rank: 2
-
FDA approves dostarlimab-gxly with chemotherapy for …
https://www.fda.gov:443/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer
WEBOn July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for...
DA: 13 PA: 34 MOZ Rank: 73
-
Dostarlimab-gxly - NCI - National Cancer Institute
https://www.cancer.gov:443/about-cancer/treatment/drugs/dostarlimab-gxly
WEB(dos-TAR-lih-mab) Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.
DA: 70 PA: 96 MOZ Rank: 57
-
Dostarlimab: A breakthrough in the field of oncology - PMC
https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9422050/
WEBJul 5, 2022 · Dostarlimab is a new drug previously used to treat endometrial cancers and has a mechanism of action that is in accordance with other PD-1/PD-L1 inhibitors. A recent clinical trial has found Dostarlimab to cure 100% of the CRC patients who were given this drug while also showing no adverse events of grade 3 or higher in any patient.
DA: 86 PA: 76 MOZ Rank: 5